![]() Further, obesity is known as a pro-inflammatory state thereby contributing importantly to eventual target organ manifestations and associated morbidity and mortality. In turn, obesity and impaired glucose tolerance/type 2 diabetes markedly increase the risk for development of renal and cardiovascular complications. The worldwide epidemic of obesity is a major predisposing factor for the ever increasing prevalence and incidence of glucose intolerance and type 2 diabetes. Conclusionĭietary Cr(pic)3 treatment of OZR does not beneficially influence glycemic status or increase the risk for oxidative DNA damage rather, the treatment attenuates indices of oxidative stress and inflammation. Finally, increased renal nitrotyrosine and cyclooxygenase-2 levels and urinary excretion of monocyte chemoattractant protein-1 of OZR were partially reversed by Cr(pic)3 treatment. However, immunostaining of kidney for 8-OHdG revealed similar staining pattern and intensity, despite significant renal accumulation of chromium in Cr(pic)3-treated groups. Urinary excretion of 8-hydroxydeoxyguanosine (8-OHdG), an index of oxidative DNA damage, was greater in the OZR than LZR dietary Cr(pic)3 treatment attenuated 8-OHdG excretion. Also, other indices of renal function or histopathology were not affected by Cr(pic)3 treatment. The OZR, irrespective of Cr(pic)3, excreted more albumin than LZR. The OZR displayed increased fasting plasma glucose and insulin in association with enlarged pancreatic islets exhibiting collagen and periodic acid Schiff-positive deposits compared to LZR Cr(pic)3 treatment did not affect these parameters. Glycemic and renal effects of Cr(pic)3 were determined in the context of indices of oxidative stress and inflammation. ![]() Male OZR were treated with diets lacking or containing 5 and 10 mg/kg of chromium, as Cr(pic)3, for 20 weeks lean Zucker rats (LZR) served as controls. Therefore, we tested the hypothesis that Cr(pic)3 treatment of obese Zucker rats (OZR) exacerbates renal abnormalities associated with dysglycemia. Potential toxicity of Cr(pic)3 should be greater for the kidney that accumulates chromium. COMPLIES WITH STANDARD U.V.Chromium picolinate (Cr(pic)3) is advocated as adjuvant therapy for impaired glycemic control, despite concerns for DNA damage. liver problems–nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes)ĬOMPLIES WITH STANDARD I.R.thinking problems, trouble concentrating.if you use steroid medicine (fluticasone, beclomethasone, prednisone, and others).diabetes (especially if you use insulin).Herbal/health supplements should be purchased from a reliable source to minimize the risk of contamination.Ĭannot use chromium picolinate if you have certain medical conditions : There are no regulated manufacturing standards in place for many herbal compounds and some marketed supplements have been found to be contaminated with toxic metals or other drugs. Chromium picolinate should not be used in place of medication prescribed for you by your doctor.Ĭhromium picolinate is often sold as an herbal supplement. Not all uses for chromium picolinate have been approved by the FDA. ![]() Uses : Chromium picolinate has been used in alternative medicine to treat chromium deficiency, as an aid to controlling blood sugar in people with diabetes or prediabetes, to lower cholesterol, and as a weight-loss supplement. The body needs only trace amounts of chromium, and deficiency of this mineral in humans is rare.Ĭhromium picolinate works together with insulin produced by the pancreas to metabolize carbohydrates. ![]() Description : Chromium is a mineral found in certain foods. ![]()
0 Comments
Leave a Reply. |